Subsequently, the patient was switched to osimertinib treatment, which resulted in a progression-free survival interval of more than 11 months.<h4>Conclusions</h4>The present results suggested that acquired VOPP1-EGFR fusion gene with T790M potentially serve an additional resistance mechanism to first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.